Proportion of time spent in the Start Room or Avoidance Room or showing a behaviour (Stimulus Contact) presented across stimuli and separately for female (n = 10) and male (n = 10)... by Sara Hintze (3216885)

Subjects:

Frequencies of different behaviours (Compartment Changes, Escape Attempts, Stimulus Orientation, Stimulus Approach, Stimulus Contact, Grunting, Barking, Excretion), the minimum dis... by Sara Hintze (3216885)

Subjects:

H& E staining investigation of CAM treated with native-orientin (5 μM), native-orientin (10 μM), NF-O (5 μM), and NF-O (10 μM). by Yashwanth Elumalai (21743452)

Subjects:

Dynamic light scattering (DLS) data of NF-O. by Yashwanth Elumalai (21743452)

Subjects:

Forest plot of the improvement in primary endpoints. by Jin-Min Gu (17915039)

Subjects:

Subgroup and sensitivity analyses for the primary outcomes. by Jin-Min Gu (17915039)

Subjects:

Forest plot of inflammatory markers. by Jin-Min Gu (17915039)

Subjects:

Flow diagram for the identification of studies included. by Jin-Min Gu (17915039)

Subjects:

Forest plot of the hospital stay length in distinct stages of patients. by Jin-Min Gu (17915039)

Subjects:

Forest plot of the second endpoint of the clinical symptom improvement. by Jin-Min Gu (17915039)

Subjects:

Kaplan-Meier curves and time-dependent Cox regression for outcome of mortality. by Jennifer M. Kwan (3350321)

Subjects:

Cox regression models for adverse cardiovascular events (ACE) and individual components of ACE. by Jennifer M. Kwan (3350321)

Subjects:

Adverse cardiovascular events by immune checkpoint inhibitor. by Jennifer M. Kwan (3350321)

Subjects:

Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events. by Jennifer M. Kwan (3350321)

Subjects:

Minimal dataset. by Jennifer M. Kwan (3350321)

Subjects:

Mean concentrations of sum monoterpenes and single monoterpenes: α-pinene, β-pinene, myrcene, limonene, β-(E)-ocimene, and α-terpineol obtained from the 10 distillation time (DT) f... by Valtcho D. Zheljazkov (627617)

Effect of DM, and/or <i>M. charantia</i> on the (I) number of corpuses lutea; (II) number of neonates, (III) weight of neonates; (IV) length of neonates levels in the control and d... by Amoura M. Abou-El-Naga (21001524)

Effect of DM, and/or <i>M. charantia</i> on the (I) glucose; (II) HOMA IR, (III) QUICKI levels; (IV) GLUT4; (V) AMPK; (VI) insulin; (VII) leptin levels in the control and different... by Amoura M. Abou-El-Naga (21001524)

Effect of DM, and/or <i>M. charantia</i> on the neurotransmitters levels, acetylcholine (I) and dopamine (II). by Amoura M. Abou-El-Naga (21001524)

Baseline Characteristics of Study Participants Stratified by Sleep Duration Categories. by Zhi Jin (3742471)

Subjects: